SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000891293-19-000039
Filing Date
2019-05-02
Accepted
2019-05-02 17:07:05
Documents
59
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cti10q03312019.htm 10-Q 977942
2 EXHIBIT 10.2 ex102-directorcompensation.htm EX-10.2 18515
3 EXHIBIT 31.1 ex311-ceo302q1fy19.htm EX-31.1 11031
4 EXHIBIT 31.2 ex312-cfo302q1fy19.htm EX-31.2 12125
5 EXHIBIT 32 ex32-ceocfo906q1fy19.htm EX-32 11919
  Complete submission text file 0000891293-19-000039.txt   4182309

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ctic-20190331.xml EX-101.INS 680754
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20190331.xsd EX-101.SCH 33972
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20190331_cal.xml EX-101.CAL 77131
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20190331_def.xml EX-101.DEF 116760
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20190331_lab.xml EX-101.LAB 468749
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20190331_pre.xml EX-101.PRE 255697
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-28386 | Film No.: 19792901
SIC: 2834 Pharmaceutical Preparations